Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy

• Status: Completed
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using more potent antibody induction treatment and/or an elective switch to sirolimus) can improve the function and survival of kidney transplants.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oxford
• Collaborators: National Health Service, United Kingdom; Novartis; Pfizer
• Treatments: Alemtuzumab; Antibodies, Monoclonal; Basiliximab; Calcineurin Inhibitors; Everolimus; Sirolimus; Tacrolimus

Criteria

Inclusion Criteria:

• men or women aged over 18 years

• recipient of kidney transplant (planned in next 24 hours)

Exclusion Criteria:

• recipients of multi-organ transplant

• previous treatment with Campath-1H

• active infection (including HIV, hepatitis B or C)

• history of anaphylaxis to humanized monoclonal antibody

• history of malignancy (except adequately treated non-melanoma skin cancer)

• loss of kidney transplant within 6 months not due to technical reasons

• medical history that might limit the individual's ability to take trial treatments for the duration of the study